32

BrainStorm

January 17, 2023

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

George Vradenburg and the Future of Alzheimer's Advocacy - Part 1

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm, host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative.  They discuss the immediate implications of the drug approval, how it will impact the Alzheimer’s movement, and what it means for the future of Alzheimer’s disease. 

Do you have feedback or an idea for the podcast? Send us a note at [email protected].
 

Support the show

BrainStorm Feed

84
April 15, 2025 | 19:43

Greg O'Brien – Advocating for Scientific Research for Alzheimer’s

Journalist and author Greg O'Brien, diagnosed with early-onset Alzheimer's over a decade ago, shares with BrainStorm host Meryl his determination t

LISTEN NOW
83
April 1, 2025 | 12:23

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 2)

In this episode of BrainStorm, host Meryl Comer continues explore the challenges of dementia diagnosis in her interview with Doreen Monks, a former

LISTEN NOW
82
March 18, 2025 | 16:54

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 1)

What if your life and career were upended with a diagnosis of Alzheimer’s only to learn eight years later that the diagnosis was wrong?  In th

LISTEN NOW